Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Aim:To develop and evaluate a whole-body physiologically based pharmacokinetic (WB-PBPK) model of bisoprolol and to simulate its exposure and disposition in healthy adults and patients with renal function impairment.Methods:Bisoprolol dispositions in 14 tissue compartments were described by perfusion-limited compartments. Based the tissue composition equations and drug-specific properties such as log P, permeability, and plasma protein binding published in literatures, the absorption and whole-body distribution of bisoprolol was predicted using the 'Advanced Compartmental Absorption Transit' (ACAT) model and the whole-body disposition model, respectively. Renal and hepatic clearances were simulated using empirical scaling methods followed by incorporation into the WB-PBPK model. Model refinements were conducted after a comparison of the simulated concentration-time profiles and pharmacokinetic parameters with the observed data in healthy adults following intravenous and oral administration. Finally, the WB-PBPK model coupled with a Monte Carlo simulation was employed to predict the mean and variability of bisoprolol pharmacokinetics in virtual healthy subjects and patients.Results:The simulated and observed data after both intravenous and oral dosing showed good agreement for all of the dose levels in the reported normal adult population groups. The predicted pharmacokinetic parameters (AUC, Cmax, and Tmax) were reasonably consistent (<1.3-fold error) with the observed values after single oral administration of doses ranging from of 5 to 20 mg using the refined WB-PBPK model. The simulated plasma profiles after multiple oral administration of bisoprolol in healthy adults and patient with renal impairment matched well with the observed profiles.Conclusion:The WB-PBPK model successfully predicts the intravenous and oral pharmacokinetics of bisoprolol across multiple dose levels in diverse normal adult human populations and patients with renal insufficiency.

[1]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[2]  Gordon M. Crippen,et al.  Predicting pKa , 2009, J. Chem. Inf. Model..

[3]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[4]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.

[5]  Mechanistic modeling. , 1995, Environmental science & technology.

[6]  J H Lin,et al.  Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[7]  G. Keating,et al.  Bisoprolol: a review of its use in chronic heart failure. , 2002, Drugs.

[8]  Thomas Singer,et al.  Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants , 2011, Clinical pharmacokinetics.

[9]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[10]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[11]  Thierry Lavé,et al.  An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. , 2005, Journal of pharmaceutical sciences.

[12]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[13]  T Lavé,et al.  Challenges and opportunities with modelling and simulation in drug discovery and drug development , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  Hugh A. Barton,et al.  Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[15]  Simon Thomas,et al.  Clinical relevance of predictive physiologically based pharmacokinetic methods , 2008, Expert opinion on drug discovery.

[16]  R. Mannhold,et al.  Calculation of molecular lipophilicity: state of the art and comparison of methods on more than 96000 compounds , 2009, Journal of pharmaceutical sciences.

[17]  I. Ijiri,et al.  A statistical analysis of the internal organ weights of normal Japanese people. , 1997, Health physics.

[18]  Shinji Yamazaki,et al.  Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model , 2011, Drug Metabolism and Disposition.

[19]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[20]  D. Moran.  Beta blockers and heart failure. , 2004, Harvard heart letter : from Harvard Medical School.

[21]  Neil Parrott,et al.  Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.

[22]  Malcolm Rowland,et al.  Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. , 2005, Journal of pharmaceutical sciences.

[23]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[24]  Thierry Lavé,et al.  Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. , 2009, Molecular pharmaceutics.

[25]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[26]  M. Jamei,et al.  Physiologically-Based Pharmacokinetics , 2011 .

[27]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[28]  W. Kirch,et al.  Pharmacokinetics of Bisoprolol During Repeated Oral Administration to Healthy Volunteers and Patients with Kidney or Liver Disease , 1987, Clinical pharmacokinetics.

[29]  P. Hinderling,et al.  Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. , 1997, Pharmacological reviews.

[30]  Martin Kuentz,et al.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  A. Chauhan,et al.  A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. , 2010, Journal of pharmaceutical sciences.

[32]  P. Christian,et al.  Variability of gastric emptying measurements in man employing standardized radiolabeled meals , 1986, Digestive Diseases and Sciences.

[33]  F Aspesi,et al.  Dissolution testing. , 1989, Bulletin of the International Union against Tuberculosis and Lung Disease.

[34]  Michael B Bolger,et al.  In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. , 2012, Molecular pharmaceutics.

[35]  P. Boesiger,et al.  Intersubject and intrasubject variability of gastric volumes in response to isocaloric liquid meals in functional dyspepsia and health 2 , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[36]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[37]  P. De Groote,et al.  Bisoprolol in the treatment of chronic heart failure , 2007, Vascular health and risk management.

[38]  M. Jamei,et al.  Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.

[39]  L. Zhang,et al.  When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective , 2009, Clinical pharmacology and therapeutics.

[40]  D. Gustafson,et al.  Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysis. , 2011, Journal of pharmaceutical sciences.

[41]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.

[42]  Michael B. Bolger,et al.  In Silico Modeling of Non-Linear Drug Absorption for the P-gp Substrate Talinolol and of Consequences for the Resulting Pharmacodynamic Effect , 2006, Pharmaceutical Research.

[43]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[44]  Lawrence X. Yu,et al.  Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development , 2011, The AAPS Journal.

[45]  D. J. Veldhuisen,et al.  Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality , 2010, European journal of heart failure.

[46]  H. Flachs,et al.  Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption. , 1990, British journal of clinical pharmacology.

[47]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008, Expert opinion on drug metabolism & toxicology.

[48]  R Gomeni,et al.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation. , 1984, Computers in biology and medicine.

[49]  Kuresh Youdim,et al.  Application of PBPK modelling in drug discovery and development at Pfizer , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[50]  Gordon M. Crippen,et al.  Predicting p K a . , 2009 .

[51]  Micaela B. Reddy,et al.  Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible , 2011, Biopharmaceutics & drug disposition.

[52]  Sheila Annie Peters,et al.  Identification of Intestinal Loss of a Drug through Physiologically Based Pharmacokinetic Simulation of Plasma Concentration-Time Profiles , 2008, Clinical pharmacokinetics.

[53]  G. Cheymol,et al.  Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers , 2004, European Journal of Clinical Pharmacology.

[54]  Lawrence X. Yu,et al.  Mechanistic Approaches to Predicting Oral Drug Absorption , 2009, The AAPS Journal.

[55]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[56]  Sheila Annie Peters,et al.  Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[57]  Hannah M. Jones,et al.  Modelling and PBPK Simulation in Drug Discovery , 2009, The AAPS Journal.

[58]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[59]  L. A. Fenu,et al.  The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools , 2007, Drug Metabolism and Disposition.

[60]  D. Papadopoulos,et al.  Low-dose Fixed Combination of Bisoprolol/Hydrochlorothiazide as First Line for Hypertension: A Review of the Rationale and Clinical Evidence , 2009, Angiology.

[61]  Marilyn E. Morris,et al.  Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships , 2009, The AAPS Journal.

[62]  K. Bühring,et al.  Basic Pharmacokinetics of Bisoprolol, a New Highly Beta1‐selective Adrenoceptor Antagonist , 1986, Journal of clinical pharmacology.

[63]  I. Nestorov,et al.  Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. , 2001, Toxicology letters.

[64]  M. Taguchi,et al.  Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 Cells. , 2008, Drug metabolism and pharmacokinetics.

[65]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[66]  Johan Gabrielsson,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .

[67]  L. Ding,et al.  LC-ESI-MS method for the determination of bisoprolol in human plasma. , 2007, Journal of pharmaceutical and biomedical analysis.